Przejdź do zawartości
Merck

Przejdź do

14-536

Białko kinazy MAP 2/Erk2, nieaktywne, ludzkie, 50 g

Unactive, N-terminal GST-tagged, recombinant human full length MAP Kinase 2, for use in Kinase Assays.

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto
50 μg

Dostępne do wysyłki DZISIAJzKuehne + Nagel Sp. z o.o.

2400,00 zł

Informacje o tej pozycji

UNSPSC Code:
12352202
NACRES:
NA.41
eCl@ss:
32160405
Biological source:
human
Recombinant:
expressed in E. coli

2400,00 zł


Dostępne do wysyłki DZISIAJSzczegóły


Zamów zamówienie zbiorcze
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


biological source

human

Quality Level

recombinant

expressed in E. coli

mol wt

Mw 67.8 kDa

manufacturer/tradename

Upstate®

technique(s)

activity assay: suitable (kinase)

NCBI accession no.

UniProt accession no.

shipped in

dry ice

General description

N-terminal GST-tagged, recombinant human full length MAP Kinase 2
Product Source: Expressed in E. coli

Application

Research Category
Metabolism

Inflammation & Immunology
Research Sub Category
Obesity

Metabolic Disorders

Osteoporosis

Arthritis

Biochem/physiol Actions

Protein Target: MAPK2
Target Sub-Family: CMGC

Physical form

Glutathione agarose affinity chromatography

Preparation Note

6 months at -20°C

Analysis Note

routinely evaluated by phosphorylation of MBP substrate

Other Notes

For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
14-51514-19814-550-M
technique(s)

activity assay: suitable (kinase)

technique(s)

activity assay: suitable (kinase)

technique(s)

activity assay: suitable (kinase)

technique(s)

activity assay: suitable (kinase)

biological source

human

biological source

human

biological source

mouse

biological source

human

recombinant

expressed in E. coli

recombinant

expressed in E. coli

recombinant

expressed in E. coli

recombinant

expressed in E. coli

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

shipped in

-

UniProt accession no.

P28482

UniProt accession no.

P28482

UniProt accession no.

P63085

UniProt accession no.

P28482

mol wt

Mw 67.8 kDa

mol wt

Mw 70 kDa

mol wt

Mw 67.8 kDa

mol wt

Mw 67.8 kDa


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Skin Sens. 1

Klasa składowania

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów



Xiaoyun Wang et al.
Scientific reports, 6, 28260-28260 (2016-06-16)
Although the translational function of tRNA has long been established, extra translational functions of tRNA are still being discovered. We previously developed a computational method to systematically predict new tRNA-protein complexes and experimentally validated six candidate proteins, including the mitogen-activated
Ivana Yen et al.
Cancer cell, 34(4), 611-625 (2018-10-10)
Targeting KRAS mutant tumors through inhibition of individual downstream pathways has had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS mutant tumors. In combination drug screens, MEK and PI3K inhibitors synergized with pan-RAF inhibitors



Numer pozycji handlu globalnego

SKUNUMER GTIN
14-53604053252622144

Questions

Reviews

No rating value

Active Filters